Related references
Note: Only part of the references are listed.Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Linda Stein Gold et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Management of psoriasis as a systemic disease: what is the evidence?
N. J. Korman
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Abby S. Van Voorhees et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
Bela J. Shah et al.
INDIAN DERMATOLOGY ONLINE JOURNAL (2020)
Molecular and Cellular Mechanisms of Itch in Psoriasis
Eriko Komiya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Influence of Itch and Pain on Sleep Quality in Atopic Dermatitis and Psoriasis
Karolina Kaaz et al.
ACTA DERMATO-VENEREOLOGICA (2019)
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
Kristina Callis Duffin et al.
BMC DERMATOLOGY (2019)
Evaluation of sPGA x BSA as an Outcome Measure and Treatment Target for Clinical Practice
Joseph F. Merola et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study
Arvin Ighani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2017)
The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment
Agnieszka Bozek et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2017)
Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis
T. H. Wong et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis
April W. Armstrong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
Robert Bissonnette et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Inter-observer reliability of the PASI in a clinical setting
Samantha Cabrera et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
P. C. M. van de Kerkhof et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment
C. Chow et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial
I. Flytstrom et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis
J Schmitt et al.
DERMATOLOGY (2005)
Share Paper
